Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50 results about "Immune cell infiltration" patented technology

Immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time

ActiveCN112011616APromote the implementation of precision medicineObjective assessment of infiltrationMicrobiological testing/measurementBiostatisticsTNM staging systemMicroarray cgh
The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.
Owner:上海顿慧医疗科技发展有限公司

Water-in-oil-in-water type vaccine adjuvant and application thereof

The invention provides a water-in-oil-water type vaccine adjuvant and application thereof. According to the technical scheme, ingredients which conform to large production demands and have immunopotentiation are preferred, according to a controlled release principle of a water-in-oil-water type microsphere, an adding mode is designed, thus the water-in-oil-water type vaccine adjuvant more effectively directly acts on an immune cell, and the immune potency is improved. Compared with an regular adjuvant in the prior art, the prepared water-in-oil-water type vaccine adjuvant has reasonable controlled release, target and an isolation characteristic, and after poultry is injected with a vaccine, the water-in-oil-water type microsphere timely metabolizes and breaks so as to comprehensively motivate a poultry lymphocyte to generate an antibody. An immune reinforcing agent with a heavy water phase can be lastingly and slowly release in a subsequent immune cell infiltration process to make bioavailability of the immune reinforcing agent maximize, it is shown that an injected part is well absorbed, an injected animal fast generates immunoprotection, and not only short-term immunity can be induced, but also long-term immunity can be induced.
Owner:天津三江永利生物科技有限公司

Analysis method of immuno prognosis diagnostic marker combination for ovarian cancer

The invention discloses an analysis method of an immune prognosis diagnosis marker combination for the ovarian cancer. The marker combination comprises the following genes: CSPG5, CXCL10, CXCL11, DKK1, PI3, TNFRSF17, DUOX1, TNFRSF13B and PAEP. The analysis method comprises the following steps of: S1, collecting and preprocessing data; S2, performing TMB score calculation and prognosis analysis; S3, performing difference analysis; S4, constructing and evaluating a TMB-immune prognosis related risk scoring model; S5, determining the relationship between clinical pathological factors and the TMB-IRS model; S6, carrying out CIBERSORT database analysis; and S7, carrying out statistical analysis. According to the analysis method, the immune risk scoring model related to TMB is constructed through nine key tumor mutation load related immune prognosis genes of the ovarian cancer, patients are divided into a high-risk group and a low-risk group, and it is proved that the high-risk group is related to poor prognosis, and the immune cell infiltration proportion of the patients in the low-risk group is higher; and prognosis prompts are provided for clinical treatment of the ovarian cancer, and the marker combination can be used as a novel biomarker and a potential treatment target for predicting ovarian cancer prognosis.
Owner:SOUTHEAST UNIV

Glutamine metabolism gene tag scoring system for predicting prognosis and treatment resistance of hepatocellular carcinoma

ActiveCN113930506AObjective assessment of overall survivalAids in treatment resistanceMicrobiological testing/measurementProteomicsOncologyChemo therapy
The invention discloses a glutamine metabolism gene tag scoring system for predicting prognosis and treatment resistance of hepatocellular carcinoma, and belongs to the technical field of biological medicine. By detecting the expression level of seven specific glutamine metabolism related genes of a hepatocellular carcinoma patient, a model can be used for judging the total lifetime of the patient, evaluating the treatment resistance of a postoperative transcatheter arterial chemoembolism patient and evaluating the immune cell infiltration degree in a tumor and the immune escape potential of a tumor cell, and the prediction capability on the liver cancer immunotherapy reaction is improved. Meanwhile, the model provided by the invention can improve the prediction accuracy of the three-year total lifetime of hepatocellular carcinoma, and compared with the prediction of the prognosis of the patient directly through the existing next-generation sequencing technology, the number of genes needing to be detected is reduced, the efficiency is improved, and the cost is reduced. As a molecular marker capable of objectively and accurately evaluating hepatocellular carcinoma treatment resistance and tumor immune state, accurate prediction and precise implementation of hepatocellular carcinoma treatment prognosis can be realized.
Owner:AFFILIATED HOSPITAL OF JIANGSU UNIV

Method for constructing tumor mutation load TMB panel and using method of tumor mutation load TMB panel

The invention discloses a method for constructing a tumor mutation load TMB panel. The method comprises the following steps: 1) acquiring transcriptome data of a tumor patient, and dividing the transcriptome data into a high TMB group and a low TMB group; 2) screening immune-related differential expression genes DEGs between the high TMB group and the low TMB group, and carrying out enrichment analysis; 3) carrying out immune cell infiltration analysis through Immune CellAI, and screening out potential key immune cells; 4) screening out tumor immunity related genes for prognosis of the patient; 5) establishing modules with different colors and a correlation matrix of immune traits possibly influencing prognosis; and 6) selecting genes with better correlation with macrophages, DC, MAIT andinfiltration integration in the WCGNA, and preliminarily obtaining a TMBIF gene panel. The invention also provides a using method of the tumor mutation load TMB panel. The tumor mutation load TMB panel constructed by the invention is low in sequencing cost and low in DNA input requirement in use, has shorter turnover time, can perform deeper sequencing, and improves the mutation detection sensitivity.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Classification method and system of immune-related disease molecular typing and subtype classifier

PendingCN113903400AExcellent treatment response rateGood choiceMedical data miningKernel methodsMolecular typingCell
The invention provides a classification method and system of immune-related disease molecular typing and a subtype classifier, and the method comprises the steps: carrying out the molecular typing in a training set through a clustering algorithm, and obtaining a plurality of subtypes stably appearing in the training set and a marker gene of each subtype; carrying out enrichment analysis on marker genes of the subtypes, carrying out immune cell infiltration evaluation on the subtypes, and obtaining various subtype categories with stable immune characteristics according to analysis and evaluation results; comparing the treatment response rates of different subtype categories through the comparison set, and determining the subtype category needing to be recognized; constructing a support vector machine model by utilizing the feature genes obtained by screening and the optimal parameter combination; and identifying whether the to-be-classified immune-related disease data is a required subtype category or not. According to the invention, immune-related disease subtypes with stable characteristics can be identified, so that accurate drug selection and economic treatment are facilitated. The invention is applicable to molecular typing and subtype classification of various immune-related diseases, and is not limited to the embodiments herein.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Application of RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and predicting model

The invention provides an application of an RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and a prediction model. According to theinvention, the expression level of RPS3A in postoperative tumor tissues of a hepatocellular carcinoma patient is detected; in clinical practice, the RPS3A can be used as a molecular marker to reflectthe infiltration level of immune cells in tumors and the molecular expression condition of immune checkpoints and guide the immunotherapy management of liver cancer patients, so that the immunological characteristics and prognosis risk of hepatocellular carcinoma can be evaluated, the formulation of a liver cancer individualized treatment scheme can be promoted, and relatively high guiding significance is achieved; meanwhile, the Nomogram prognosis prediction model is constructed on the basis of RPS3A molecules, compared with traditional TNM and BCLC stages, better prediction efficiency and accuracy are achieved, liver cancer patients are enabled to obtain more clinical net income, and the RPS3A molecule can be applied to clinically and accurately judging the postoperative survival time of hepatocellular carcinoma patients.
Owner:JUSBIO SCI SHANGHAI CO LTD

Application of RGS19 in construction of lung squamous cell carcinoma prognosis prediction model as diagnostic marker

The invention relates to the technical field of biomedicine and particularly relates to application of RGS19 in construction of a lung squamous cell carcinoma prognosis prediction model as a diagnostic marker. According to the application, the biomarker RGS19 is used through being combined with other clinical indexes, and lung squamous cell carcinoma prognosis detection can be made in an assisted manner; screening and constructing are carried out after carrying out full-transcriptome sequencing and machine learning based on lung squamous cell carcinoma specimens subjected to large-sample antitumor immunotherapy, and prognosis conditions of a lung squamous cell carcinoma sufferer can be efficiently and accurately predicted; and meanwhile, comprehensive evaluation on an immunization microenvironment of a tumor is achieved according to correlation between the risk of the tumor and different immunized cell infiltration levels, immunization-related channels and key immunization check point inhibitor expression levels, so that an effective instruction opinion is provided for clinicians for therapy decision making for the lung squamous cell carcinoma sufferer, occurrence of invalid therapy is reduced, and thus, the therapy cost and discomfort experience of the sufferer are reduced.
Owner:JINSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products